Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Regulation of adiponectin secretion in human subcutaneous and omental adipose tissue: effects of pioglitazone and endothelin-1: a pilot study.

Mahadik SR, Lele RD, Mehtalia SD, Deo SS, Parikh V.

J Assoc Physicians India. 2013 Apr;61(4):244-8.

PMID:
24482963
2.

Adiponectin secretion and response to pioglitazone is depot dependent in cultured human adipose tissue.

Phillips SA, Ciaraldi TP, Oh DK, Savu MK, Henry RR.

Am J Physiol Endocrinol Metab. 2008 Oct;295(4):E842-50. doi: 10.1152/ajpendo.90359.2008. Epub 2008 Jul 29.

3.

The expression of FTO in human adipose tissue is influenced by fat depot, adiposity, and insulin sensitivity.

Bravard A, Veilleux A, Disse E, Laville M, Vidal H, Tchernof A, Rieusset J.

Obesity (Silver Spring). 2013 Jun;21(6):1165-73. doi: 10.1002/oby.20110.

4.

The impact of obesity on secretion of adiponectin multimeric isoforms differs in visceral and subcutaneous adipose tissue.

Kovacova Z, Tencerova M, Roussel B, Wedellova Z, Rossmeislova L, Langin D, Polak J, Stich V.

Int J Obes (Lond). 2012 Oct;36(10):1360-5. doi: 10.1038/ijo.2011.223. Epub 2011 Dec 6.

PMID:
22143618
5.

Differences in adiponectin protein expression: effect of fat depots and type 2 diabetic status.

Fisher FM, McTernan PG, Valsamakis G, Chetty R, Harte AL, Anwar AJ, Starcynski J, Crocker J, Barnett AH, McTernan CL, Kumar S.

Horm Metab Res. 2002 Nov-Dec;34(11-12):650-4.

PMID:
12660876
6.

Subcutaneous abdominal adipose tissue subcompartments: potential role in rosiglitazone effects.

Walker GE, Marzullo P, Verti B, Guzzaloni G, Maestrini S, Zurleni F, Liuzzi A, Di Blasio AM.

Obesity (Silver Spring). 2008 Sep;16(9):1983-91. doi: 10.1038/oby.2008.326.

7.

Insulin-sensitizing effects of thiazolidinediones are not linked to adiponectin receptor expression in human fat or muscle.

Li W, Tonelli J, Kishore P, Owen R, Goodman E, Scherer PE, Hawkins M.

Am J Physiol Endocrinol Metab. 2007 May;292(5):E1301-7. Epub 2007 Jan 9. Erratum in: Am J Physiol Endocrinol Metab. 2009 Feb;296(2):E402.

8.

Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes.

Hirose H, Kawai T, Yamamoto Y, Taniyama M, Tomita M, Matsubara K, Okazaki Y, Ishii T, Oguma Y, Takei I, Saruta T.

Metabolism. 2002 Mar;51(3):314-7.

PMID:
11887166
9.

Short-term beta-adrenergic regulation of leptin, adiponectin and interleukin-6 secretion in vivo in lean and obese subjects.

Goossens GH, Jocken JW, van Baak MA, Jansen EH, Saris WH, Blaak EE.

Diabetes Obes Metab. 2008 Nov;10(11):1029-38. doi: 10.1111/j.1463-1326.2008.00856.x. Epub 2008 Apr 22.

PMID:
18435774
11.

Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone.

Motoshima H, Wu X, Sinha MK, Hardy VE, Rosato EL, Barbot DJ, Rosato FE, Goldstein BJ.

J Clin Endocrinol Metab. 2002 Dec;87(12):5662-7.

PMID:
12466369
12.

Pioglitazone increases the proportion of small cells in human abdominal subcutaneous adipose tissue.

McLaughlin TM, Liu T, Yee G, Abbasi F, Lamendola C, Reaven GM, Tsao P, Cushman SW, Sherman A.

Obesity (Silver Spring). 2010 May;18(5):926-31. doi: 10.1038/oby.2009.380. Epub 2009 Nov 12.

13.

[Depot-specific expression of retinol-binding protein 4 in human adipose tissue and their relationship with obesity and insulin resistance].

Lu HY, Li XF, Mu PW, Jiang W, Zeng LY.

Zhonghua Yi Xue Za Zhi. 2010 Dec 28;90(48):3395-8. Chinese.

PMID:
21223811
14.

Parallel down-regulation of FOXO1, PPARĪ³ and adiponectin mRNA expression in visceral adipose tissue of class III obese individuals.

Hammes TO, Costa Cdos S, Rohden F, Margis R, de Almeida JC, Padoin AV, Mottin CC, Guaragna RM.

Obes Facts. 2012;5(3):452-9. doi: 10.1159/000339574. Epub 2012 Jun 30.

PMID:
22797373
15.

Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes.

Bodles AM, Banga A, Rasouli N, Ono F, Kern PA, Owens RJ.

Am J Physiol Endocrinol Metab. 2006 Nov;291(5):E1100-5. Epub 2006 Jun 27.

16.

Human mesenteric adipose tissue plays unique role versus subcutaneous and omental fat in obesity related diabetes.

Yang YK, Chen M, Clements RH, Abrams GA, Aprahamian CJ, Harmon CM.

Cell Physiol Biochem. 2008;22(5-6):531-8. doi: 10.1159/000185527. Epub 2008 Dec 9.

PMID:
19088435
17.

[Expression of omentin in adipose tissues in obese and type 2 diabetic patients].

Cai RC, Wei L, DI JZ, Yu HY, Bao YQ, Jia WP.

Zhonghua Yi Xue Za Zhi. 2009 Feb 17;89(6):381-4. Chinese.

PMID:
19567114
18.

In vitro and in vivo effects of metformin on human adipose tissue adiponectin.

Zulian A, Cancello R, Girola A, Gilardini L, Alberti L, Croci M, Micheletto G, Danelli P, Invitti C.

Obes Facts. 2011;4(1):27-33. doi: 10.1159/000324582. Epub 2011 Feb 16.

PMID:
21372608
20.

Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes.

Harte AL, McTernan PG, McTernan CL, Smith SA, Barnett AH, Kumar S.

Diabetes Obes Metab. 2003 Sep;5(5):302-10.

PMID:
12940867
Items per page

Supplemental Content

Write to the Help Desk